Cargando…

Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention

Detalles Bibliográficos
Autores principales:	Topalis, Dimitri, Snoeck, Robert, Andrei, Graciela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588366/ https://www.ncbi.nlm.nih.gov/pubmed/26501093 http://dx.doi.org/10.1016/j.ebiom.2015.07.042

Ejemplares similares

Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage
por: De Schutter, Tim, et al.
Publicado: (2013)

CRISPR/Cas9 Editing of the Polyomavirus Tumor Antigens Inhibits Merkel Cell Carcinoma Growth In Vitro
por: Temblador, Arturo, et al.
Publicado: (2019)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1
por: Topalis, Dimitri, et al.
Publicado: (2016)

Organotypic Epithelial Raft Cultures as a Three-Dimensional In Vitro Model of Merkel Cell Carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness
por: Trompet, Erika, et al.
Publicado: (2021)

Poxviruses Bearing DNA Polymerase Mutations Show Complex Patterns of Cross-Resistance
por: Andrei, Graciela, et al.
Publicado: (2022)

HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance
por: Günthard, Huldrych F., et al.
Publicado: (2016)

Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir
por: De Schutter, Tim, et al.
Publicado: (2013)

BKTyper: Free Online Tool for Polyoma BK Virus VP1 and NCCR Typing
por: Martí-Carreras, Joan, et al.
Publicado: (2020)

Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice
por: Mertens, Barbara, et al.
Publicado: (2018)

Cidofovir Activity against Poxvirus Infections
por: Andrei, Graciela, et al.
Publicado: (2010)

Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase
por: Topalis, D., et al.
Publicado: (2016)

Highly active antiretroviral treatment for the prevention of HIV transmission
por: Granich, Reuben, et al.
Publicado: (2010)

Lignosulfonic acid exhibits broad-spectrum anti-HIV and anti-HSV activity and has potential for microbicidal applications
por: Férir, Geoffrey, et al.
Publicado: (2014)

Advances and Perspectives in the Management of Varicella-Zoster Virus Infections
por: Andrei, Graciela, et al.
Publicado: (2021)

Dual anti-HSV and anti-HIV activity of the lantibiotic Labyrinthopeptin A1
por: Férir, Geoffrey, et al.
Publicado: (2014)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

Tenofovir for prevention of mother to child transmission of hepatitis B in migrant women in a resource-limited setting on the Thailand-Myanmar border: a commentary on challenges of implementation
por: Bierhoff, M., et al.
Publicado: (2020)

Global implementation of PrEP for HIV prevention: setting expectations for impact
por: Pyra, Maria N, et al.
Publicado: (2019)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019)

Identification of Immune Activation Profiles That May Predict Morbidity During Antiretroviral Therapy Treated HIV Infection
por: Funderburg, Nicholas T.
Publicado: (2016)

Evaluating AVAHAN’s design, implementation and impact: lessons learned for the HIV Prevention Community
por: Laga, Marie, et al.
Publicado: (2011)

HIV prevention is not enough: child survival in the context of prevention of mother to child HIV transmission
por: Kuhn, Louise, et al.
Publicado: (2009)

Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan
por: Kanda, Naoki, et al.
Publicado: (2021)

Two commentaries on ‘Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children’
por: Coovadia, Hoosen, et al.
Publicado: (2009)

Impact of COVID-19 pandemic in adolescents on HIV treatment
por: Wyk, Brian Van, et al.
Publicado: (2022)

Novel Therapeutics for Epstein–Barr Virus
por: Andrei, Graciela, et al.
Publicado: (2019)

The pathogenesis of HIV infection: stupid may not be so dumb after all
por: Smith, Stephen M
Publicado: (2006)

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
por: McKinnon, Lyle R., et al.
Publicado: (2018)

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
por: Horizon, Arash A, et al.
Publicado: (2011)

Within but without: human rights and access to HIV prevention and treatment for internal migrants
por: Todrys, Katherine Wiltenburg, et al.
Publicado: (2009)

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)
por: Matheron, Sophie, et al.
Publicado: (2018)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

The Downstream Impacts of High Drug Costs for PrEP Have Hindered the Promise of HIV Prevention
por: Farrow, Kenyon
Publicado: (2022)

Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: Efficient synthesis and antiviral activity
por: Hocková, Dana, et al.
Publicado: (2011)

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients
por: Engell, Christian A., et al.
Publicado: (2011)

Enhancing HIV Treatment Access and Outcomes Amongst HIV Infected Children and Adolescents in Resource Limited Settings
por: Goga, Ameena Ebrahim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_im7b4hkq84nrpmk2j1hg86ap8g